Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Cash from Investing Activities: 2009-2025

Historic Cash from Investing Activities for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to -$2.1 million.

  • Lifecore Biomedical's Cash from Investing Activities rose 22.71% to -$2.1 million in Q2 2025 from the same period last year, while for May 2025 it was -$6.4 million, marking a year-over-year increase of 65.13%. This contributed to the annual value of -$6.4 million for FY2025, which is 65.13% up from last year.
  • As of Q2 2025, Lifecore Biomedical's Cash from Investing Activities stood at -$2.1 million, which was down 235.82% from $1.5 million recorded in Q1 2025.
  • Lifecore Biomedical's Cash from Investing Activities' 5-year high stood at $65.2 million during Q1 2022, with a 5-year trough of -$17.5 million in Q2 2022.
  • Over the past 3 years, Lifecore Biomedical's median Cash from Investing Activities value was -$3.1 million (recorded in 2024), while the average stood at -$2.6 million.
  • In the last 5 years, Lifecore Biomedical's Cash from Investing Activities surged by 139,607.41% in 2021 and then slumped by 2,136.28% in 2023.
  • Lifecore Biomedical's Cash from Investing Activities (Quarterly) stood at -$5.4 million in 2021, then rose by 29.06% to -$3.8 million in 2022, then declined by 10.73% to -$4.3 million in 2023, then surged by 42.74% to -$2.4 million in 2024, then climbed by 22.71% to -$2.1 million in 2025.
  • Its last three reported values are -$2.1 million in Q2 2025, $1.5 million for Q1 2025, and -$2.4 million during Q4 2024.